Some studies suggest that changes of drug metabolism that are rooted from CYP2D6 genetic variants make insufficient effects on the therapeutic levels of venlafaxine and that CYP2D6 genotyping would not forecast the treatment efficacy of venlafaxine in patients with depression [66,67,68,69]. The gene discussed is CYP2D6; the disease is depressive symptom measurement.